Bayer Phase III REVEAL Study Meets Primary Endpoints in Cardiac Amyloidosis ? • Bayer says the Phase III REVEAL study of investigational PET radiotracer iodine 124 evuzamitide met its primary endpoints for sensitivity and specificity in diagnosing cardiac amyloidosis. • Majority-read sensitivity was 94% and specificity was 86%; sensitivity was 96% for ATTR amyloidosis and 95% for AL amyloidosis. • Bayer plans to discuss the data and a potential regulatory submission with the FDA and other health authorities; iodine 124 evuzamitide is not currently approved in any country. 30-AUG-2026 04:40 PM ET